Summit Therapeutics Inc. (SMMT) Stock
SMMT Key Statistics
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
CEO: Robert W. Duggan. Company website
SMMT — Frequently Asked Questions
What is the SMMT stock price today?
Summit Therapeutics Inc. (SMMT) trades at $16.64, down 6.67% on the day, as of Nov 12, 2026 09:30 UTC.
What is Summit Therapeutics Inc.'s market cap?
Summit Therapeutics Inc. has a market capitalisation of $13.27B, calculated from the live SMMT share price and shares outstanding.
What is the P/E ratio of SMMT?
SMMT has no meaningful price-to-earnings ratio: Summit Therapeutics Inc. lost $1.07 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Summit Therapeutics Inc. make?
Summit Therapeutics Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for SMMT?
SMMT has traded between $12.07 and $29.23 over the past 52 weeks, and the last price is 43.1% below that high.
Is Summit Therapeutics Inc. profitable?
Yes. Summit Therapeutics Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for SMMT?
Wall Street analysts rate SMMT Buy, with an average price target of $32.14, 93.1% above the current price.
What sector is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Summit Therapeutics Inc.?
Robert W. Duggan is the chief executive of Summit Therapeutics Inc., which employs 265 people.
Where can I track SMMT in real time?
QFI Terminal shows SMMT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SMMT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SMMT in Terminal See plans